SEC Form 4
Mirum Pharmaceuticals, Inc. (MIRM) insider trading
In the 12 months to Oct 26, 2026, 5 MIRM insiders reported open-market sales of $29.8M across 23 filings; one director bought $9.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $29.8M
- 23 filings · 5 insiders
- Open-market purchases
- $9.0M
- 1 filing · Patrick J. Heron, Director
- Pre-arranged sales (10b5-1)
- 21 of 23
- $25.4M of $29.8M sold (85%)
Who traded MIRM, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
MIRM daily close from Oct 27, 2025 to Oct 26, 2026, between $64.10 and $128.57, last $82.82. 23 sale and 1 purchase filings by 6 insiders, marked at their filing dates. Michael G. Grey, Director: sold $11.1M across 3 filings, first filed Nov 25, 2025, last Dec 23, 2025. Christopher Peetz, CHIEF EXECUTIVE OFFICER: sold $10.3M across 4 filings, first filed Jun 2, 2026, last Sep 3, 2026. Patrick J. Heron, Director: bought $9.0M across 1 filing, first filed Jan 27, 2026, last Jan 27, 2026. Jolanda Howe, SVP, GLOBAL CONTROLLER: sold $4.9M across 5 filings, first filed Jun 18, 2026, last Sep 3, 2026. Saira Ramasastry, Director: sold $1.9M across 8 filings, first filed Dec 19, 2025, last Jun 2, 2026. Eric Bjerkholt, CHIEF FINANCIAL OFFICER: sold $1.7M across 3 filings, first filed Jun 9, 2026, last Aug 12, 2026.
Largest mark · tap a row for others
Patrick J. Heron · Director
Purchase $8,999,984
131,425 shares at $68.48 avg
Filed Jan 27, 2026 · traded Jan 23
Close on filing date $99.27
Michael G. Grey · Director
Director
$11.1M soldChristopher Peetz · CHIEF EXECUTIVE OFFICER
CHIEF EXECUTIVE OFFICER
$10.3M soldPatrick J. Heron · Director
Director
$9.0M boughtJolanda Howe · SVP, GLOBAL CONTROLLER
SVP, GLOBAL CONTROLLER
$4.9M soldSaira Ramasastry · Director
Director
$1.9M soldEric Bjerkholt · CHIEF FINANCIAL OFFICER
CHIEF FINANCIAL OFFICER
$1.7M soldOpen-market trades
24 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Michael G. Grey | Director | $11.1M | — | 3 | 100% of sales | |
| Christopher Peetz | CHIEF EXECUTIVE OFFICER | $10.3M | — | 4 | 100% of sales | |
| Patrick J. Heron | Director | — | $9.0M | 1 | — | |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | $4.9M | — | 5 | 18% of sales | |
| Saira Ramasastry | Director | $1.9M | — | 8 | 79% of sales | |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | $1.7M | — | 3 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Christopher Peetz CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 30,000 | $98.68 | $3.0M | 216,128 | |
traded | Jolanda Howe SVP, GLOBAL CONTROLLER | SalePre-arranged (10b5-1) | 658 | $100.00 | $65.8K | 616 | |
traded | Jolanda Howe SVP, GLOBAL CONTROLLER | Sale | 40,000 | $100.00 | $4.0M | 1,274 | |
traded | Eric Bjerkholt CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 6,001 | $99.90 | $599.5K | 36,355 | |
traded | Christopher Peetz CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 20,000 | $98.92 | $2.0M | 196,609 | |
traded | Jolanda Howe SVP, GLOBAL CONTROLLER | SalePre-arranged (10b5-1) | 1,840 | $105.29 | $193.7K | 1,274 | |
traded | Eric Bjerkholt CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 5,000 | $122.25 | $611.3K | 44,057 | |
traded | Christopher Peetz CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 20,000 | $122.27 | $2.4M | 196,019 | |
traded | Jolanda Howe SVP, GLOBAL CONTROLLER | SalePre-arranged (10b5-1) | 2,721 | $120.00 | $326.5K | 3,114 | |
traded | Jolanda Howe SVP, GLOBAL CONTROLLER | SalePre-arranged (10b5-1) | 2,594 | $101.95 | $264.5K | 5,835 | |
traded | Eric Bjerkholt CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 5,000 | $93.82 | $469.1K | 44,788 | |
traded | Saira Ramasastry Director | Sale | 3,977 | $100.00 | $397.7K | 0 | |
traded | Christopher Peetz CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 30,000 | $95.84 | $2.9M | 198,186 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $109.47 | $218.9K | 0 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $96.90 | $193.8K | 0 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $90.76 | $181.5K | 0 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $102.09 | $204.2K | 0 | |
traded | Patrick J. Heron Director | Purchase | 131,425 | $68.48 | $9.0M | 459,010 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $90.99 | $182.0K | 0 | |
traded | Michael G. Grey Director | SalePre-arranged (10b5-1) | 50,000 | $78.00 | $3.9M | 0 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 5,000 | $80.00 | $400.0K | 0 | |
traded | Saira Ramasastry Director | SalePre-arranged (10b5-1) | 2,000 | $69.73 | $139.5K | 1,000 | |
traded | Michael G. Grey Director | SalePre-arranged (10b5-1) | 50,000 | $74.00 | $3.7M | 0 | |
traded | Michael G. Grey Director | SalePre-arranged (10b5-1) | 50,000 | $70.00 | $3.5M | 0 |
GET /stocks/filings/vX/form-4?tickers=MIRM&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"MIRM"
],
"issuer_cik": "0001759425",
"owner_cik": "0001614740",
"accession_number": "0001614740-26-000013",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-01",
"issuer_name": "Mirum Pharmaceuticals, Inc.",
"issuer_trading_symbol": "MIRM",
"owner_name": "Peetz Christopher",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CHIEF EXECUTIVE OFFICER",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 21688,
"transaction_price_per_share": 98.91,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 194440,
"transaction_value": 2145160.08,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026."
},
{
"id": "F4",
"description": "The weighted average sale price for the transaction reported was $98.91, and the range of prices were between $98.49 and $99.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."
}
]
},
{
"tickers": [
"MIRM"
],
"issuer_cik": "0001759425",
"owner_cik": "0001974200",
"accession_number": "0001974200-26-000013",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-02",
"issuer_name": "Mirum Pharmaceuticals, Inc.",
"issuer_trading_symbol": "MIRM",
"owner_name": "Howe Jolanda",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "SVP, GLOBAL CONTROLLER",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 658,
"transaction_price_per_share": 100,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 616,
"transaction_value": 65800,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 67 records
- Option exercises46 records
- Tax withholding (sold to cover)19 records
- Gifts1 record
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Mirum Pharmaceuticals, Inc.'s CEO sold stock?
Yes. Christopher Peetz (CEO) sold 100,000 shares ($10.3M) between Jun 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is MIRM’s insider data?
These are MIRM Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track MIRM insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for MIRM every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.